HL7® FHIR® Te Aho o Te Kahu, Cancer Control Agency Implementation Guide
0.1.0 - CI Build

HL7® FHIR® Te Aho o Te Kahu, Cancer Control Agency Implementation Guide, published by Te Aho o Te Kahu, Cancer Control Agency. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7NZ/cca/ and changes regularly. See the Directory of published versions

ValueSet: ESMO-MCBS Evaluation Form

Official URL: https://standards.digital.health.nz/fhir/ValueSet/sact-esmo-mcbs-evaluation-form Version: 0.1.0
Active as of 2026-05-21 Computable Name: EsmoMcbsEvaluationForm

The evaluation forms used in the ESMO Magnitude of Clinical Benefit Scale

References

Logical Definition (CLD)

 

Expansion

Expansion performed internally based on codesystem ESMO-MCBS Evaluation Form v0.1.0 (CodeSystem)

This value set contains 12 concepts

SystemCodeDisplay (en)JSONXML
https://standards.digital.health.nz/ns/sact-esmo-mcbs-evaluation-form  ST-1aEvaluation Form 1a: For RCTs evaluating new approaches to adjuvant therapy or new potentially curative therapies
https://standards.digital.health.nz/ns/sact-esmo-mcbs-evaluation-form  ST-1bEvaluation Form 1b: For single arm de-escalation studies in the adjuvant setting
https://standards.digital.health.nz/ns/sact-esmo-mcbs-evaluation-form  ST-2aEvaluation Form 2a: For therapies that are not likely to be curative with primary endpoint of OS
https://standards.digital.health.nz/ns/sact-esmo-mcbs-evaluation-form  ST-2bEvaluation Form 2b: For therapies that are not likely to be curative with primary endpoint PFS
https://standards.digital.health.nz/ns/sact-esmo-mcbs-evaluation-form  ST-2cEvaluation Form 2c: For therapies that are not likely to be curative with primary endpoint other than OS or PFS or equivalent (non-inferiority) studies
https://standards.digital.health.nz/ns/sact-esmo-mcbs-evaluation-form  ST-3Evaluation Form 3: For single-arm studies in orphan diseases and for diseases with high unmet need when primary outcome is PFS or ORR
https://standards.digital.health.nz/ns/sact-esmo-mcbs-evaluation-form  HM-1aEvaluation Form 1a: For RCTs evaluating new approaches to new potentially curative therapies
https://standards.digital.health.nz/ns/sact-esmo-mcbs-evaluation-form  HM-1bEvaluation Form 1b: For single arm therapies with curative intent and de-escalation studies
https://standards.digital.health.nz/ns/sact-esmo-mcbs-evaluation-form  HM-2aEvaluation Form 2a: For therapies that are not likely to be curative with primary endpoint of OS
https://standards.digital.health.nz/ns/sact-esmo-mcbs-evaluation-form  HM-2bEvaluation Form 2b: For therapies that are not likely to be curative with primary endpoint PFS
https://standards.digital.health.nz/ns/sact-esmo-mcbs-evaluation-form  HM-2cEvaluation Form 2c: For therapies that are not likely to be curative with primary endpoint other than OS or PFS or equivalent (non-inferiority) studies
https://standards.digital.health.nz/ns/sact-esmo-mcbs-evaluation-form  HM-3Evaluation Form 3: For single-arm studies in orphan diseases and for diseases with high unmet need when primary outcome is PFS or ORR

Explanation of the columns that may appear on this page:

Level A few code lists that FHIR defines are hierarchical - each code is assigned a level. In this scheme, some codes are under other codes, and imply that the code they are under also applies
System The source of the definition of the code (when the value set draws in codes defined elsewhere)
Code The code (used as the code in the resource instance)
Display The display (used in the display element of a Coding). If there is no display, implementers should not simply display the code, but map the concept into their application
Definition An explanation of the meaning of the concept
Comments Additional notes about how to use the code